William Blair Issues Pessimistic Forecast for VRTX Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – William Blair decreased their FY2025 EPS estimates for shares of Vertex Pharmaceuticals in a report issued on Tuesday, November 4th. William Blair analyst M. Minter now expects that the pharmaceutical company will post earnings of $15.95 per share for the year, down from their prior estimate of $15.99. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $15.63 per share. William Blair also issued estimates for Vertex Pharmaceuticals’ Q4 2025 earnings at $4.23 EPS.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.58 by $0.22. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The company had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. During the same period in the prior year, the firm earned $4.38 earnings per share. Vertex Pharmaceuticals’s revenue was up 11.0% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS.

Several other equities research analysts have also weighed in on VRTX. BMO Capital Markets set a $530.00 price target on Vertex Pharmaceuticals and gave the company an “outperform” rating in a research report on Tuesday, August 5th. JPMorgan Chase & Co. raised their price objective on Vertex Pharmaceuticals from $517.00 to $530.00 and gave the company an “overweight” rating in a research report on Wednesday, October 8th. Canaccord Genuity Group reduced their target price on shares of Vertex Pharmaceuticals from $424.00 to $411.00 and set a “hold” rating on the stock in a research report on Wednesday, August 6th. Stifel Nicolaus decreased their price target on shares of Vertex Pharmaceuticals from $455.00 to $445.00 and set a “hold” rating for the company in a research note on Tuesday. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Vertex Pharmaceuticals in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and twelve have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $489.45.

Vertex Pharmaceuticals Stock Performance

VRTX stock opened at $416.25 on Friday. Vertex Pharmaceuticals has a fifty-two week low of $362.50 and a fifty-two week high of $519.88. The company has a market capitalization of $106.72 billion, a price-to-earnings ratio of 29.75 and a beta of 0.36. The business’s 50 day moving average price is $404.18 and its two-hundred day moving average price is $430.46.

Institutional Trading of Vertex Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Mason & Associates Inc purchased a new position in Vertex Pharmaceuticals in the third quarter worth about $257,000. Camden National Bank grew its holdings in shares of Vertex Pharmaceuticals by 2.1% during the third quarter. Camden National Bank now owns 20,892 shares of the pharmaceutical company’s stock valued at $8,182,000 after buying an additional 430 shares during the last quarter. Abich Financial Wealth Management LLC bought a new stake in shares of Vertex Pharmaceuticals during the third quarter valued at approximately $73,000. Public Sector Pension Investment Board raised its holdings in Vertex Pharmaceuticals by 13.9% in the 3rd quarter. Public Sector Pension Investment Board now owns 22,418 shares of the pharmaceutical company’s stock worth $8,780,000 after acquiring an additional 2,744 shares during the last quarter. Finally, Atria Investments Inc raised its holdings in Vertex Pharmaceuticals by 10.3% in the 3rd quarter. Atria Investments Inc now owns 25,919 shares of the pharmaceutical company’s stock worth $10,151,000 after acquiring an additional 2,418 shares during the last quarter. 90.96% of the stock is owned by hedge funds and other institutional investors.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.